CDIX: Nova revenue rises but heavy interest, preferred dividends fuel going-concern risk

Snapshot - Cardiff Lexington Corporation (PINK: CDIX)

What's happening inside: the company's healthcare subsidiary (Nova) is growing revenue and operating profit, but the parent's financing costs, heavy preferred dividend obligations and complex capital structure are eroding results and creating going-concern risk. Management restated cash-flow presentation (non‑cash interest reclassification) and continues to remediate material weaknesses in controls.

Key facts & statistics (Q1 2025 vs Q1 2024 where shown)
- Revenue: $2,915,567 (Q1 2025) vs $2,322,132 (Q1 2024)
- Cost of sales: $1,075,034 vs $948,154
- Gross profit: $1,840,533 vs $1,373,978 (gross margin 63.13% vs 59.17%)
- Operating expenses: $1,296,599 vs $1,154,986
- Income from operations: $543,934 vs $218,992
- Interest expense: $993,114 (Q1 2025) vs $376,269 (Q1 2024)
- Net loss (continuing ops): $(450,777) vs $(171,792)
- Net loss (period): $(450,777) vs $(283,104)
- Preferred stock dividends: $(245,445) for Q1 2025
- Net loss attributable to common shareholders: $(696,222) vs $(434,738)
- Cash (end period): $996,758 vs $1,188,185 (Dec 31, 2024 beginning balance $1,188,185)
- Accounts receivable, net: $17,502,055 (Mar 31, 2025)
- Line of credit outstanding: $10,210,485 (Mar 31, 2025) with accrued interest $411,300
- Total assets: $25,330,628; Total liabilities: $18,230,516; Stockholders' equity: $2,036,047; Accumulated deficit: $(73,645,307)
- Allowance for credit losses: $249,799; credit loss expense recognized Q1 2025: $112,727
- Weighted average shares outstanding (basic & diluted): 15,315,657 (Q1 2025) vs 3,818,218 (Q1 2024) - explains EPS movement
- Going concern: Company discloses substantial doubt and says additional capital is required

Positive points
- Top-line growth: revenue rose ~25.6% YoY to $2.92M driven by higher patient volume and more complex procedures.
- Improving gross margin: up to 63.13% from 59.17%, indicating service mix or cost control in clinical delivery.
- Operating profitability at the subsidiary level: healthcare segment shows strong operating income (healthcare operating income reported $1,454,339), meaning core operations can be profitable absent corporate/financing drag.
- Cash conservation vs prior period: net cash used in operating activities improved to $(491,420) from $(1,035,021).

Negative / risks (income statement and balance sheet drivers)
- Interest & financing cost is crushing operating results: interest expense of $993,114 in one quarter turned a positive operating result into a large net loss. Most interest relates to the receivable financing line of credit.
- High leverage on receivables: $10.21M outstanding on the receivable line (with significant accrued interest) creates refinancing and liquidity risk-facility matures Sept 29, 2025.
- Preferred dividends: $245k in the quarter further reduces what's available to common shareholders.
- Large accounts receivable balance ($17.5M) and an increase in the allowance / provision ($112,727) - settlement realization and cash collection take 18-24 months; company reduced its settlement rate historically (from 49% to ~42.9% in prior periods), increasing working capital strain.
- Complex, dilutive capital structure: many series of preferred shares, convertible notes and subsequent post‑period conversions that materially increase common share count (post‑period conversions noted in filings), creating dilution risk.
- Governance & reporting issues: restatements (cash-flow classification, reclassification of credit loss), ongoing material weaknesses in internal control - heightens execution and disclosure risk.
- Going-concern: explicit statement that additional capital is required; inability to raise funds could lead to curtailment or cessation of operations.

Near-term catalysts & monitoring items
- Line-of-credit maturity (Sept 29, 2025) and ability to refinance or reduce the $10.21M balance.
- Cash collections from accounts receivable and any improvement in settlement realization rates (management targets 24‑month lookback and active negotiation policy).
- Progress on remediation of internal control weaknesses and absence of further restatements.
- Equity or debt raises: management indicates need for $5M-$10M (low‑end) to execute acquisition strategy - any successful raise would materially alter liquidity and dilution dynamics.
- Post‑period preferred-to-common conversions noted in the filing - monitor total outstanding common shares and EPS dilution.

Bottom line: operationally the healthcare business shows revenue growth and healthy gross margins, but financing costs, preferred dividends and a leveraged receivables financing structure convert operating profit into a sizable net loss. The balance sheet and going‑concern disclosure mean the company's near-term trajectory depends on successful refinancing or capital raises and improved AR collections. Investors should weigh the core healthcare performance against high financing risk, heavy preferred obligations and ongoing control deficiencies.